Vivos Therapeutics (VVOS) EBITDA Margin (2020 - 2026)
Vivos Therapeutics (VVOS) posted quarterly EBITDA Margin of 128.67% for Q1 2026, up 124.0% year-over-year from 57.44% in Q1 2025, and up 22.9% quarter-over-quarter from 166.89% in Q4 2025.
Vivos Therapeutics (VVOS) EBITDA Margin (2020 - 2026) Analysis & Trends
Vivos Therapeutics (VVOS) has reported EBITDA Margin for 7 consecutive years, with 128.67% the latest figure, recorded in Q1 2026.
- In Q1 2026, EBITDA Margin rose 124.0% year-over-year to 128.67%; the TTM figure through Mar 2026 stood at 115.47% (down 3819.0% YoY), while the FY2025 annual figure was 114.05%, down 3973.0% from the prior year.
- EBITDA Margin improved to 128.67% in Q1 2026 per VVOS's latest filing, from 166.89% in the prior quarter.
- Across five years, EBITDA Margin topped out at 47.76% in Q2 2024 and bottomed at 182.19% in Q1 2022.
- Historically, EBITDA Margin has averaged 120.9% across 5 years, with a median of 127.36% in 2025.
- Annual changes were most pronounced in 2024 — EBITDA Margin surged 8529 bps — and 2025, when it sank 9101 bps.
- Vivos Therapeutics' EBITDA Margin stood at 153.49% in 2022, then advanced by 17 bps to 127.25% in 2023, then surged by 40 bps to 75.88% in 2024, then slumped by 120 bps to 166.89% in 2025, then increased by 23 bps to 128.67% in 2026.
- Business Quant data shows VVOS's EBITDA Margin at 128.67% in Q1 2026, 166.89% in Q4 2025, and 69.79% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.61 Bn | 194.01 Bn | 7.27 Bn | 13.44% |
| 2 | Stryker | 127.81 Bn | 124.34 Bn | 4.50 Bn | 25.18% |
| 3 | Medtronic | 119.04 Bn | 109.82 Bn | 6.41 Bn | 19.10% |
| 4 | Boston Scientific | 73.68 Bn | 73.14 Bn | 3.85 Bn | 21.65% |
| 5 | Edwards Lifesciences | 51.96 Bn | 47.71 Bn | 1.35 Bn | 29.48% |
| 6 | Dexcom | 34.36 Bn | 32.41 Bn | 830.00 Mn | 24.33% |
| 7 | GE HealthCare Technologies | 33.83 Bn | 31.72 Bn | 2.18 Bn | 13.96% |
| 8 | Koninklijke Philips | 26.36 Bn | 23.04 Bn | 4.55 Bn | 10.30% |
| 9 | Steris | 23.06 Bn | 22.58 Bn | 684.20 Mn | 19.15% |
| 10 | Vivos Therapeutics | 4.97 Mn | 3.17 Mn | 2.95 Mn | -87.81% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -128.67% |
| Dec 31, 2025 | -166.89% |
| Sep 30, 2025 | -69.79% |
| Jun 30, 2025 | -127.36% |
| Mar 31, 2025 | -129.91% |
| Dec 31, 2024 | -75.88% |
| Sep 30, 2024 | -68.52% |
| Jun 30, 2024 | -47.76% |
| Mar 31, 2024 | -110.70% |
| Dec 31, 2023 | -127.25% |
| Sep 30, 2023 | -110.27% |
| Jun 30, 2023 | -133.05% |
| Mar 31, 2023 | -129.76% |
| Dec 31, 2022 | -153.49% |
| Sep 30, 2022 | -127.34% |
| Jun 30, 2022 | -166.44% |
| Mar 31, 2022 | -182.19% |
| Dec 31, 2021 | -168.66% |
| Sep 30, 2021 | -121.05% |
| Jun 30, 2021 | -90.30% |